Merck completed the acquisition of Pandion Therapeutics for $1.85bn.

Merck, a global healthcare company, completed the acquisition of Pandion Therapeutics, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $1.85bn. “This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational characteristics. Pandion has applied its TALON technology to develop a robust pipeline of candidates designed to re-balance the immune response with potential applications across a wide array of autoimmune diseases,” Dean Y. Li, Merck President of Research Laboratories. On March 4, 2021, Merck began tender offer.